Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$7.48 USD

7.48
684,260

+0.35 (4.91%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $7.47 -0.01 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Lavina Shahu headshot

4 Toxic Stocks That Are Detrimental to Your Portfolio's Health

Accurately identifying toxic stocks and getting rid of them at the right time can protect your portfolio. You should sell ANGO, DH, CWST and EVA.

Implied Volatility Surging for AngioDynamics (ANGO) Stock Options

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.

AngioDynamics (ANGO) Reports Q3 Loss, Lags Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 2.28%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

KORU Medical Systems Inc. (KRMD) Reports Q4 Loss, Misses Revenue Estimates

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 20% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in AngioDynamics (ANGO) Stock?

Investors need to pay close attention to AngioDynamics (ANGO) stock based on the movements in the options market lately.

AngioDynamics (ANGO) Q2 Earnings, Revenues Top Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in second-quarter fiscal 2023.

AngioDynamics (ANGO) Surpasses Q2 Earnings and Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 200% and 1.65%, respectively, for the quarter ended November 2022. Do the numbers hold clues to what lies ahead for the stock?

SARTORIUS (SARTF) Surges 7.4%: Is This an Indication of Further Gains?

SARTORIUS (SARTF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

The Cooper Companies (COO) Q4 Earnings Miss Estimates

The Cooper Companies (COO) delivered earnings and revenue surprises of -11% and 1.03%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical, Inc. (ISRG) Up 24.6% Since Last Earnings Report: Can It Continue?

Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Rimmi Singhi headshot

4 Toxic Stocks That May Stress You Out Amid Market Turmoil

Just like identifying promising stocks, detecting toxic stocks and dumping them at the right time are crucial to safeguarding one's portfolio from big losses.

AngioDynamics (ANGO) Q1 Earnings, Revenues Lag Estimates

AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2023.

AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of -200% and 1.99%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments but forex remains a woe.

Why Is AngioDynamics (ANGO) Up 15.4% Since Last Earnings Report?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

AngioDynamics (ANGO) Q4 Earnings in Line, Revenues Beat Mark

AngioDynamics (ANGO) registers strong revenue growth in Med Tech and Med Device businesses, as well as in its GBUs, in fourth-quarter fiscal 2022.

AngioDynamics (ANGO) Q4 Earnings Match Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates

Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for March 8th

ANGO, BURL, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on March 8, 2022.

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.